Loss of cellular adhesion leads to the progression of breast cancer through acquisition of anchorage independence, also known as resistance to anoikis. Although inactivation of E-cadherin is essential for acquisition of anoikis resistance, it has remained unclear how metastatic breast cancer cells counterbalance the induction of apoptosis without E-cadherin-dependent cellular adhesion. We report here that E-cadherin inactivation in breast cancer cells induces PI3K/AKT-dependent FOXO3 inhibition and identify FOXO3 as a novel and direct transcriptional activator of the pro-apoptotic protein BMF. As a result, E-cadherin-negative breast fail to upregulate BMF upon transfer to anchorage independence, leading to anoikis resistance. Conversely, expression of BMF in E-cadherin-negative metastatic breast cancer cells is sufficient to inhibit tumour growth and dissemination in mice. In conclusion, we have identified repression of BMF as a major cue that underpins anoikis resistance and tumour dissemination in E-cadherin-deficient metastatic breast cancer.
Development and homeostasis of glandular structures such as the mammary gland depend on spatiotemporal induction of apoptosis upon loss of cell-cell and cell-matrix attachment, a process known as anoikis. 1, 2 Proper anoikis regulation ensures the formation of hollow lumen within a glandular epithelium structure by induction of apoptosis in selective non-polarised luminal epithelial cells that line the ductal structures. 3, 4 In the mammary gland, the pro-apoptotic proteins BIM and BMF induce apoptosis upon cell detachment and as such contribute to the formation of mammary ductal lumen. 5, 6 Anoikis is regulated by an intricate regulation of the balance between pro-apoptotic and anti-apoptotic proteins. 7 Antiapoptotic BCL-2 family proteins (BCL-2, BCL-xL and MCL1) compete with the pro-apoptotic molecules (BIM, PUMA, NOXA, BID, BAD or BMF) for binding to BAK and BAX to prevent mitochondrial membrane permeabilisation and subsequent apoptosis. Expression of pro-apoptotic proteins can be induced by a variety of stresses, including DNA damage, nutrient deprivation, heat and hypoxia. 8 BMF appears to specifically function to induce anoikis in epithelial cells. 5, 9 It is, however, still controversial whether activation of factors such as BMF is induced through transcriptional activation or by posttranslational events in the cytosol. 10 Correct execution of apoptosis in luminal mammary cells is deregulated during the early stages of breast cancer, such as atypical hyperplasia and ductal carcinoma in situ, resulting in filling of the mammary duct with anoikis-resistant cells. 11 Several studies have shown that activation of oncogenic growth factor receptor (GFR) signalling can induce aberrant filling of the luminal space. 3, 5, 12 Similar effects have been observed upon inhibition of pro-apoptotic players such as BIM, BMF and p53, 5, 6, 13 indicating that either GFR activation and/or the inhibition of distal pro-apoptotic effectors underlie anchorage independence of breast cancer cells. Indeed, mutations in the PI3K and p53 pathway are among the most observed mutations in epithelial cancers, including breast cancer. 14 Moreover, hyperactivation of PI3K and its downstream effector AKT/PKB can lead to repression of apoptosis through phosphorylation-dependent inactivation of pro-apoptotic proteins, such as BAD. 5, 15, 16 Enhanced growth factor signalling can also be induced through downregulation of the epithelial adherens junction (AJ). 17 ,18 E-cadherin is the core component of the AJ and a master regulator of epithelial integrity, linking the cell membrane to the cytoskeleton. 19 Although loss of E-cadherin in the mammary gland is not tolerated, [20] [21] [22] mammary-specific E-cadherin inactivation following loss of p53 in mice leads to the acquisition of anoikis resistance of tumour cells and subsequent dissemination, demonstrating E-cadherin loss as a prerequisite for metastatic disease progression. 23 Despite its repression by growth factor signals, the apoptotic machinery is functionally intact in cancer cells. Targeting the apoptotic machinery has become increasingly interesting in cancer therapy, as intervention strategies using novel BH-3-only protein mimetic compounds in combination with dual specificity inhibitors of PI3K and mTOR have shown promising results. 24, 25 Here we have identified BMF as a direct transcriptional target of FOXO3 in breast cancer cells. Our data show that FOXO-dependent BMF expression is repressed in E-cadherin-negative and metastatic breast cancer cells and that expression of BMF is sufficient to inhibit tumour growth and dissemination in mice. We have thereby linked loss of E-cadherin to a cell intrinsic inhibition of BMF-dependent anoikis, a crucial step in malignant tumour progression.
Results
Anoikis-resistant breast cancer cells restrain the expression of BMF. To identify the proteins that control anchorage independence of metastatic breast cancer cells, we cultured E-cadherin-expressing anchorage-dependent and anoikisresistant E-cadherin-negative breast cancer cells from mouse and human origin in suspension (Sus). Under these conditions, the non-metastatic mouse mammary carcinoma cell line Trp53 Δ/Δ -4 and human MCF7 underwent anoikis as previously demonstrated. 20, 26 In contrast, mouse and human E-cadherin-negative mILC1 and MDA-MB-231 cells were anoikis resistant (Figures 1a and b) .
To determine which of the key anti-apoptotic and proapoptotic molecules were induced during anoikis, we assayed the protein and mRNA expression levels of the anti-apoptotic family members BCL2, BCL-XL and MCL1 and the proapoptotic NOXA, PUMA, BIM, BID and BMF. We observed that all cell lines upregulated BCL2 protein levels and showed increased BID cleavage under anchorage-independent conditions regardless of E-cadherin status. For NOXA and PUMA, no changes were detected in protein levels (Supplementary Figure S1A ). In line with previous findings, 5 Figures S2A  and B) . We observed that, although E-cadherin-negative cells induced BMF under anchorage-independent conditions, the expression levels were 3-10-fold lower relative to Trp53 Δ/Δ -4 and MCF7. These data demonstrate that anchorageindependent E-cadherin-negative cells restrain transcriptional upregulation of BMF, a key inducer of anoikis.
Despite the fact that BMF is the major pro-apoptotic factor that showed uniform transcriptional upregulation in suspension settings, at the protein level both BMF and BIM are increased (Figures 1c and d and Supplementary Figures S1B and C) . To determine whether these two BH3-only factors are specifically required to induce anoikis, we performed loss-of-function studies and assessed the effect of BMF and/or BIM loss on anoikis resistance of mouse and human E-cadherin-positive cells. Using two independent targeting sequences, we induced knockdown and observed that loss of either BMF or BIM led to a significant increase in anoikis resistance of Trp53 Δ/Δ and MCF7 cells (Figures 2a-f ). Concomitant knockdown of BMF and BIM also resulted in a significant increase in anoikis resistance when compared with controls (Figures 2a-f) . Overall, our data does not indicate that dual inhibition of BMF and BIM has an additive effect when compared with the single BMF knockdown experiments (Figures 2a and b) . In short, our data demonstrate that BMF and BIM both contribute to the induction of anoikis in E-cadherin-positive breast cancer cells. Further, our data indicate that BMF and BIM are nonredundant and have overlapping functions in the regulation of anoikis of E-cadherin-expressing cells. Overall, we show that BIM and BMF expression is increased upon transfer to anchorage-independent conditions to induce anoikis. However, our data indicate that, in contrast to BIM, the upregulation of BMF under these conditions is transcriptionally regulated.
Loss of E-cadherin results in anoikis resistance and restricts BMF expression. To determine whether E-cadherin loss is causal to the repression of BMF expression in breast cancer, we generated E-cadherin knockout cell lines using the CRISPR/Cas9 system. Guide RNAs targeting the E-cadherin locus were expressed in Trp53 Δ/Δ and MCF7 cells, which were subsequently fluorescent-activated cell sorted (FACS) based on E-cadherin expression, resulting in E-cadherin-negative cell lines. In contrast to control cells, the E-cadherin knockout cell lines failed to establish E-cadherinbased cell-cell junctions and consequently grew dispersed as solitary cells (Figure 3a) . As expected, we observed that E-cadherin loss in mouse and human cells resulted in the acquisition of anoikis resistance (Figure 3b ). Importantly, we noted a significant reduction of BMF expression in E-cadherin knockout cell lines relative to control cells upon transfer to anchorage independence (Figures 3c and d) . These results confirm that loss of E-cadherin is causal to the acquisition of anoikis resistance and show that loss of E-cadherin leads to transcriptional repression of BMF expression upon loss of cell-matrix attachment.
BMF expression is inhibited by growth factor signallingdependent repression of FOXO3. Because BMF was transcriptionally regulated upon transfer to anchorage independence, we hypothesised that either direct transcription repression or inhibition of a transcription factor could underlie the differential BMF expression in anoikis-resistant breast cancer cells. We therefore analysed the human genomic BMF promoter region and identified two FOXO consensusbinding sites (TTGTTTA). FOXOs are directly regulated and suppressed by canonical PI3K/AKT signalling and known transcription factors for the pro-apoptotic genes BIM, NOXA and PUMA. To determine whether FOXO3 activation was sufficient to induce anoikis in E-cadherin-negative cells, we cultured mILC1-iFOXO3.A3 and MDA-MB-231-iFOXO3.A3 in suspension and assayed anchorage-independent survival. Addition of Dox triggered anoikis in mILC1 (Figure 4b ), confirming that FOXO activation is indeed sufficient to prevent anchorage independence in E-cadherin-negative breast cancer cells. Although MDA-MB-231-iFOXO3.A3 cells showed a modest increase in BMF expression upon expression of FOXO3 (Supplementary Figure S4B) , this did not lead to anoikis, which indicates that the induced BMF levels were insufficient to cause apoptosis in these anchorage-independent breast cancer cells.
Activation of the PI3K/AKT pathway by GFR signalling and ectopic expression of either oncogenic PI3K E545K or myristoylated AKT1 results in repression of anoikis in mammary epithelial cells. 5 Interestingly, we have previously shown that inactivation of E-cadherin function in cancer cells results in hypersensitisation of GFR signalling without activating mutations. 18 To confirm that active PI3K/AKT signalling, which is an established upstream inhibitor of FOXO, controls anoikis resistance, we cultured mILC1 cells and the MCF7-ΔCDH1 cells in suspension and inhibited AKT activation using AKTi, and observed that AKTi resulted in a twofold increase in anoikis (Figures 5a and b) . More important, we could show that AKT inhibition resulted in a 2-3-fold upregulation of BMF mRNA and protein expression in anchorage-independent cells (Figures 5c-e) .
In conclusion, our data show that E-cadherin-negative metastatic breast cancer cells restrain anoikis through PI3K/ AKT signalling, a cue that subsequently inhibits FOXO3-dependent transcriptional activation of its pro-apoptotic target BMF.
Upregulation of BMF expression restrains anchorageindependent tumour growth and metastasis of E-cadherin-negative mammary cancer in mice. Because BMF was the major pro-apoptotic factor upregulated in anoikis-sensitive breast cancer cell lines, we determined whether induction of BMF expression was sufficient to induce anoikis in E-cadherin-negative breast cancer cells. To this end, we stably introduced a Dox-inducible BMF cDNA expression system (iBMF) in mILC1 and MDA-MB-231 cells (Figure 6a ) and assayed anoikis resistance. Expression of BMF was indeed sufficient to cause a marked increase in apoptosis in both cell types (Figures 6b and c) . Moreover, treating mILC1 and MDA-MB-231 cells with increasing concentrations of the BH3-mimetic drug ABT-199 induced a dose-dependent execution of apoptosis (Figure 6d ), suggesting that anchorage-independent E-cadherin-deficient breast cancer cells have a lower threshold for the BH3-only protein-dependent execution of anoikis. Together, these results show that increased levels of BMF or inhibition of BCL2 using the BMF-mimetic ABT-199 is sufficient to induce apoptosis in E-cadherin-negative cells, especially in an anchorage-independent setting.
As anoikis resistance is an excellent prognosticator of E-cadherin-negative breast cancer growth and metastasis, 20, 23 we investigated the effect of BMF expression on tumour growth in vivo. To this end, we orthotopically transplanted 10,000 mILC1 cells carrying either an empty vector or the iBMF expression vector in recipient mice and monitored tumour growth. Once tumours reached an average volume of 100 mm 3 , we induced BMF expression by feeding mice Dox-containing chow. Treatment of mILC1 cells carrying the empty expression vector with Dox either at a 100 mm 3 or when metastasis was detected using bioluminescence imaging (BLI) did not result in significant changes in tumour growth (Figure 7a ). In contrast, BMF expression induced a significant reduction in tumour growth (Figure 7b) . Moreover, induction of BMF expression when metastases were detected led to a robust 19-fold decrease in primary tumour volume (Figure 7c) . Importantly, we observed a reduction in metastasis formation based upon BMF expression on thoracic BLI in Dox-fed mice when compared with control mice (Figures 7d-h) .
In closing, our data establish that restriction of FOXO3-dependent BMF expression underpins anchorageindependent tumour growth and metastasis of E-cadherinnegative breast cancer cells.
Discussion
Acquisition of anchorage independence through evasion of apoptosis is a hallmark of cancer. 30 Metastatic cells have shifted the regulation of pro-apoptotic and anti-apoptotic mechanisms toward survival and have thereby gained the possibility to bypass the induction of anoikis during dissemination. Activation of growth factor signalling in cancer cells is essential for anoikis resistance owing to modulation of expression and activity of apoptotic factors. 25 Others and we have demonstrated that inactivation of E-cadherin underpins anoikis resistance in breast cancer cells, a finding that appears to depend on hyper-sensitisation of GFR signalling through AKT/PKB and ERK upon dismantling of the AJ complex. 17, 18, 20, 23, 31 As these mechanisms confer constitutive activation of GFR signals in breast cancer cells, it provides a clear rationale for the maintenance of anoikis resistance in E-cadherin-deficient breast cancer cells. Although AKT/PKB and ERK can control the posttranslational modulation of BAD, BIM and BAX, our current data show that anoikis-resistant breast cancer cells restrain BMF transcription, the main proapoptotic factor uniformly expressed in E-cadherin-expressing breast cancer cells upon transfer to anchorage independence. 15, 16, 32 Elegant studies by the Brugge laboratory have identified BIM and BMF as key anoikis regulators of luminal mammary cells, a process counterbalanced by constitutive activation of growth factor-induced PI3K/AKT pathways. 5, 6 However, the underlying mechanism that prevented metastatic breast cancer cells from expressing BMF upon loss of anchorage remained unclear. As we detected clear changes in BMF mRNA levels upon transfer to anchorage independence when comparing breast cancer cells in the context of E-cadherin expression, we probed for transcriptional upstream cues, which resulted in our finding that FOXOs are key players in the regulation of BMF expression in breast cancer.
BMF can directly compete for BAK/BAX binding with BCL2 and thereby drive apoptosis. Our data indicate that the increase in BMF expression, rather than the levels of BLC2, is the rate-limiting factor driving breast cancer cell survival. First, the robust upregulation in BMF mRNA expression in anoikis-sensitive cells combined with reduced BMF expression in anoikis-resistant cells led us to think that a specific BMF threshold should be reached to induce anoikis. Second, although anoikis-resistant cells induced BMF transcription in the absence of anchorage, this did not trigger anoikis, despite expressing comparable levels of BCL2 when compared with anoikis-sensitive cells. In line with this, we did not detect differences in the expression levels of BCL2 upon transfer to anchorage independence between cell lines. Finally, we could force anoikis-resistant cells to undergo apoptosis by ectopic expression of BMF or treatment with ABT-199. Together, our data show that loss of the AJ leads to GFR-induced signals that block FOXO-dependent BMF expression, a feature that is essential for survival in breast cancer cells during metastasis. Our results indicate that FOXO-dependent transcription of BMF may be subject of epigenetic regulation as well. Although we have ectopically activated FOXO3 under anchoragedependent and -independent conditions, we detected further enhanced FOXO3 binding at the BMF promoter in suspension. The chromatin state of the BMF locus is expected to influence FOXO3 binding, as it is known that FOXO3 prefers to bind genomic regions associated with activating epigenetic marks. 33, 34 Histone deacetylase (HDAC) activity has been reported as a negative regulator of BMF expression, because inhibition of HDACs results in BMF expression in multiple human cancer cell lines. 35, 36 How BMF is regulated posttranscriptionally remains to be fully characterised, but it was previously described that phosphorylation of ERK2 can inactivate BMF function. 37, 38 In line with these findings, complementing HDAC inhibition with inhibitors of mitogenic signalling, that is, B-RAF, augments the pro-apoptotic effect of BMF. 39 This might also explain why BMF induction does not directly lead to apoptosis in anchorage-independent MDA-MB-231 cells that show a constitutively elevated growth factor signalling owing to oncogenic KRAS and B-RAF mutations. 40 Loss of BMF has been linked to tumour suppression in several cancer types. 41 Preclinical intervention strategies using BH3-only mimetics as monotherapy have been successful but mostly in lymphoid malignancies. 42, 43 Recent studies indicated that BH3-mimetics can be used to treat nonlymphoid cancers but mostly in combination with oestrogen antagonists, proteasome inhibitors, specific PI3K-mTOR inhibitors or chemotherapy. 24, [44] [45] [46] [47] [48] [49] As previous findings from our laboratory demonstrated that E-cadherin-negative lobular breast cancer depends on p120-catenin-mediated activation of RhoA, Rock and subsequent actomyosin contraction, 26 we anticipate that dual inhibition of these pathways might be successful in E-cadherin-negative cancers that are not driven by oncogenic activation of GFR pathways. Although we do not yet know whether RhoA-Rock signals converge onto the GFR-AKT-FOXO axis in the regulation of anoikis resistance, the fact that FOXO expression had no effect on survival of B-RAF/KRAS-mutated MDA-MB-231 cells seems to be in line with this assumption. Moreover, given that human invasive lobular carcinoma mostly expresses ER and responds to oestrogen antagonists, our findings provide an additional option to improve current treatment regimens in lobular breast cancer by using a combination BH3-mimetics and ERtargeted drugs.
In conclusion, we have linked activation of GFR pathways to inhibition of FOXO3-dependent BMF expression and the regulation of anchorage-independent tumour growth and metastasis in E-cadherin-negative metastatic breast cancer cells.
Materials and Methods Cell lines. Mouse breast cancer cell lines Trp53
Δ/Δ -4 (KP8) and mILC1 (KEP1) were derived from tumours that developed in female K14cre;Trp53 F/F and K14cre; Cdh1 F/F ;Trp53 F/F mice and cultured as described previously. 23 Human breast cancer cell lines MCF7 and MB-MDA-231 were verified by STR analysis and cultured as described. 18 Constructs, lentiviral transduction and transfections. Lentiviral cDNA expression vectors expressing iBMF, iFOXO3 and iFOXO3.A3 were generated using Gateway cloning in the pINDUCER20 Dox-inducible expression system. 50 Guide RNAs for Cdh1.1 and Cdh1.2 CRISPR were cloned into the lentiviral pSicoR CRISPR/Cas9 vector 51 using BsmBI restriction sites (Supplementary Table S1 ). After lentiviral transduction, cells were selected for incorporation using puromycin and subsequently FACS-sorted based on E-cadherin expression (DECMA-1, 1 : 2000; Abcam no. 11512, Cambridge, UK). BMF and BIM knockdown in Trp53 Δ/Δ -4 cells was achieved by lentiviral transduction of pLKO1-shBMF (TRCN0000009716 (shBMF #1) and TRCN0000009717 (shBMF #2)) and pLKO1-shBIM (TRCN0000231244 (shBIM #1) and TRCN0000231246 (shBIM #2), Sigma-Aldrich, Zwijndrecht, The Netherlands), followed by puromycin selection. For MCF7, siRNA smartpools targeting BMF, BIM or control siRNA (Dharmacon M-004393-04-0005 and M-004383-02-0005, Lafayette, CO, USA) were reversetransfected using HiPerfect (Qiagen, Venlo, The Netherlands) at a final siRNA concentration of 40 nM. Forty-eight hours after transfection, cells were harvested and seeded for anoikis assays. 50, 51 Immunoblotting and antibodies. Proteins were detected using SDS-PAGE and subsequent western blotting analysis with primary antibodies recognising BAD (CST-9292, Cell Signaling Technology, Leiden, The Netherlands), BIM (CST-2819) BMF (human: CST-5889, mouse: ENZO-17A9), BID (SC-11423 Santa Cruz, Heidelberg, Germany), AKT/PKB (CST), FOXO1 (CST-29H4), FOXO3 (H144 Santa Cruz), NOXA (SP7122p Acris, Herford, Germany), PUMA (CST-4976) and BCL2 (CST-2876) used at 1 : 2000. Primary antibodies were detected by secondary HRP-conjugated antibodies targeting mouse, rabbit and rat IgG and visualised using chemiluminescence (Bio-Rad, Veenendaal, The Netherlands).
Immunofluorescence. Cells were grown on glass coverslips, fixed using icecold methanol and blocked with 2% BSA (Invitrogen, Breda, The Netherlands) and 0.1% normal goat serum (Invitrogen). Cells were stained with mouse anti-p120 (BD616134, 1 : 500 overnight), Alexa Fluor 555-conjugated mouse anti-E-cadherin, (1 : 200, BD560064, 2 h at room temperature) and DAPI (Sigma-Aldrich). Secondary 563-conjugated goat anti-mouse antibodies were used for visualisation on a Zeiss LSM700 confocal microscope (Sliedrecht, The Netherlands).
Quantitative real-time PCR. mRNA was isolated from live cells using the Qiagen RNeasy Kit (Qiagen). cDNA synthesis was performed using the iScript cDNA Synthesis Kit (Bio-Rad). Real-time PCR was performed using SYBR green FastStart master mix (Roche, Woerden, The Netherlands) in the CFX Connect Real-time PCR detection system (Bio-Rad). Target genes were amplified using the specific primer pairs (Supplementary Table S1 ), and specificity was confirmed by analysis of the melting curves. Target gene expression levels were normalised to GAPDH, PBDG and TUBA1A levels.
Anoikis assays. Anoikis resistance was analysed by seeding six-well ultra-low cluster polystyrene culture dishes (Corning, Corning, NY, USA) with 50 000 cells/ml. After 24 h, cells were harvested and resuspended in 100 ml of Annexin-V buffer supplemented with Annexin-V (IQ Products, Groningen, The Netherlands) and propidium iodide (Sigma-Aldrich). Anoikis was defined as the Annexin-V and propidium iodide-positive population and quantified using a FACSCalibur (BD Biosciences, Breda, The Netherlands).
Chromatin immunoprecipitation. MCF7-iFOXO3 cells were grown under adherent (Ad) or suspension (Sus) conditions in the absence or presence of Dox and treated with the allosteric AKT inhibitor VIII 1 h prior to harvesting to ensure full FOXO activation. Immunoprecipitations were performed on 20 × 10 6 cells with 5 μg rabbit anti-FOXO3 (Santa Cruz H144) and 5 μg of normal rabbit IgG (Santa Cruz). ChIPs were performed as previously described. 52 Orthotopic transplantations and tumour watch. For longitudinal tumour growth and dissemination experiments, 10 000 mILC1 cells were transplanted in the fourth inguinal mouse mammary gland of Nude-recipient mice as described previously. 26 Primary tumours were allowed to develop to a volume of 100 mm 3 at which point expression of BMF was induced by feeding Dox-containing chow (Ssniff, Soest, Germany). Alternatively, BMF expression was induced when lung metastasis were detected using BLI of the thorax (42 × 10 3 photons/s/cm 2 /sr). Tumour volumes and lung metastases were followed in time as described using a Biospace ϕ imager (Nesles la Vallée, France). 26 All animal experiments were approved by the Utrecht University Animal Experimental Committee (DEC-ABC no. 2012.III.05.044).
